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Abstract: 
 
Background: Thevetia peruviana (Pers.) K. Schum or Cascabela peruviana (L.) Lippold 
(commonly known as ayoyote, codo de fraile, lucky nut, or yellow oleander), native to Mexico 
and Central America, is a medicinal plant used traditionally to cure diseases like ulcers, scabies, 
hemorrhoids and dissolve tumors. The purpose of this study was to evaluate the cytotoxic, 
antiproliferative and apoptotic activity of methanolic extract of T. peruviana fruits on human 
cancer cell lines. 
 
Methods: The cytotoxic activity of T. peruviana methanolic extract was carried out on human 
breast, colorectal, prostate and lung cancer cell lines and non-tumorigenic control cells 
(fibroblast and Vero), using the MTT assay. For proliferation and motility, clonogenic and 
wound-healing assays were performed. Morphological alterations were monitored by trypan blue 
exclusion, as well as DNA fragmentation and AO/EB double staining was performed to evaluate 
apoptosis. The extract was separated using flash chromatography, and the resulting fractions 
were evaluated on colorectal cancer cells for their cytotoxic activity. The active fractions were 
further analyzed through mass spectrometry. 
 
Results: The T. peruviana methanolic extract exhibited cytotoxic activity on four human cancer 
cell lines: prostate, breast, colorectal and lung, with values of IC50 1.91 ± 0.76, 5.78 ± 2.12, 
6.30 ± 4.45 and 12.04 ± 3.43 μg/mL, respectively. The extract caused a significant reduction of 
cell motility and colony formation on all evaluated cancer cell lines. In addition, morphological 
examination displayed cell size reduction, membrane blebbing and detachment of cells, 
compared to non-treated cancer cell lines. The T. peruviana extract induced apoptotic cell death, 
which was confirmed by DNA fragmentation and AO/EB double staining. Fractions 4 and 5 
showed the most effective cytotoxic activity and their MS analysis revealed the presence of the 
secondary metabolites: thevetiaflavone and cardiac glycosides. 
 
Conclusion: T. peruviana extract has potential as natural anti-cancer product with critical effects 
in the proliferation, motility, and adhesion of human breast and colorectal cancer cells, and 
apoptosis induction in human prostate and lung cancer cell lines, with minimal effects on non-
tumorigenic cell lines. 
 
Keywords: Cytotoxic activity | Anti-proliferative activity | Motility| Apoptosis | Human cancer 
cells | Flavonoid | Cardiac glycosides 
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Abstract
Background: Thevetia peruviana (Pers.) K. Schum or Cascabela peruviana (L.) Lippold (commonly known as ayoyote,
codo de fraile, lucky nut, or yellow oleander), native to Mexico and Central America, is a medicinal plant used
traditionally to cure diseases like ulcers, scabies, hemorrhoids and dissolve tumors. The purpose of this study was to
evaluate the cytotoxic, antiproliferative and apoptotic activity of methanolic extract of T. peruviana fruits on human
cancer cell lines.
Methods: The cytotoxic activity of T. peruviana methanolic extract was carried out on human breast, colorectal, prostate
and lung cancer cell lines and non-tumorigenic control cells (fibroblast and Vero), using the MTT assay. For proliferation
and motility, clonogenic and wound-healing assays were performed. Morphological alterations were monitored by
trypan blue exclusion, as well as DNA fragmentation and AO/EB double staining was performed to evaluate apoptosis.
The extract was separated using flash chromatography, and the resulting fractions were evaluated on colorectal cancer
cells for their cytotoxic activity. The active fractions were further analyzed through mass spectrometry.
Results: The T. peruviana methanolic extract exhibited cytotoxic activity on four human cancer cell lines: prostate, breast,
colorectal and lung, with values of IC50 1.91 ± 0.76, 5.78 ± 2.12, 6.30 ± 4.45 and 12.04 ± 3.43 μg/mL, respectively. The
extract caused a significant reduction of cell motility and colony formation on all evaluated cancer cell lines. In addition,
morphological examination displayed cell size reduction, membrane blebbing and detachment of cells, compared to
non-treated cancer cell lines. The T. peruviana extract induced apoptotic cell death, which was confirmed by DNA
fragmentation and AO/EB double staining. Fractions 4 and 5 showed the most effective cytotoxic activity and their MS
analysis revealed the presence of the secondary metabolites: thevetiaflavone and cardiac glycosides.
Conclusion: T. peruviana extract has potential as natural anti-cancer product with critical effects in the proliferation,
motility, and adhesion of human breast and colorectal cancer cells, and apoptosis induction in human prostate and lung
cancer cell lines, with minimal effects on non-tumorigenic cell lines.
Keywords: Cytotoxic activity, Anti-proliferative activity, Motility, Apoptosis, Human cancer cells, Flavonoid,
Cardiac glycosides
Background
Cancer is one of the most important causes of death
worldwide. In 2012, 8.2 million cancer-related deaths
were reported and the number of new cases is expected
to rise by about 70% over the next two decades [1]. Can-
cer is characterized by the uncontrolled and invasive
growth of cells. The most peculiar feature of cancer cells
is their ability to metastasize to other specific organs.
For example, prostate and colon cancer metastasize to
bones and liver, respectively; lung cancer cells spread to
adrenal glands, liver, brain, and bones, while breast cancer
cells metastasize to lungs and bones [2]. For the most
important adenocarcinomas, such as lung, breast, or
colorectal cancer, the treatment is barely effective, due
to metastatic disease responding only transiently to conven-
tional treatments [3]. Therefore, scientists are still utilizing
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new alternatives in attempts to find novel compounds and
strategies for the treatment of this disease [4].
Plants are a valuable source of new biologically active
molecules due to the presence of hundreds of biologic-
ally active components [5]. One of the plant families i.e.,
Apocynaceae, is well-known for anticancer activities,
mainly in the genera of Catharanthus, Nerium, Stro-
phanthus, Apocynum and Thevetia [6]. Thevetia peruviana
(Pers.) K. Schum, also known as Cascabela peruviana (L.)
Lippold, yellow oleander or lucky nut in the West Indies,
shows a diverse array of properties ranging from being a
cardiotonic to a toxin. T. peruviana plant has been used
traditionally for the treatment of gastrointestinal and in-
flammatory diseases, heart failures and skin tumors [7, 8].
All parts of the plant are poisonous due to the presence of
cardiac toxins, but the fruit of T. peruviana, is the most
toxic part of the plant because it has the highest and diverse
content of cardiac glycosides. There are many known cases
of intentional and accidental poisoning of humans through
ingestion of fruits and leaves [9]. Whereas about 10 fruits
consumed may be fatal for an adult, a single fruit may be
lethal for a child. The common clinical set of symptoms re-
sembles digitalis poisoning with marked nausea, vomiting,
abdominal pain, diarrhea, dysrhythmias, and hyperkalemia
[10]. Although the anticancer potential of parts of T. per-
uviana plant, such as leaves, bark and seeds has been evalu-
ated against human gastric and pancreatic cancer cell lines
[11], the anticancer potential of T. peruviana fruit is still
unknown because only a few cardiac glycosides have been
identified and examined as cytotoxic agents. Therefore, the
T. peruviana fruit extract has been investigated in this
study to explore its anticancer potential against the most
common cancer types (lung, breast, prostate and colorec-
tal), in terms of morphological analysis, motility and cell ad-
hesive properties, DNA damage and induction of apoptosis
in human cancer cell lines.
Methods
A T. peruviana plant specimen was collected in San
Nicolás de los Garza, N.L., México (25°43′59.57″N, 100°
16′4.75″W). Botanical authentication of the material
was performed by the Botany Department Staff of Facul-
tad de Ciencias Biológicas, UANL. A specimen of T. per-
uviana was recently deposited in the Herbarium of the
Facultad de Ciencias Biológicas, Universidad Autónoma
de Nuevo León (voucher UNL-028732).
Extraction and preparation of plant samples for testing
The plant extracts were obtained from samples (20 g) of
dried roots, leaves, or aerial parts through maceration
with methanol (3 × 300 mL) at room temperature for
24 h and under continuous shaking. The methanolic ex-
tracts were filtered and evaporated under reduced pres-
sure using a rotary evaporator (Yamato RE801). Samples
were stored at −20 °C prior to further experiments. For
the cytotoxicity assays, the dried methanol extract was
dissolved in dimethylsulfoxide (DMSO) in order to obtain
a final concentration of 100 mg/mL (stock) and diluted in
PBS (phosphate buffer saline). DMSO concentration in
the culture medium was less than 0.1%. Doxorubicin
(10 μg/mL, Zytokil) treated cells and untreated cells were
used as positive control and negative control, respectively.
The methanolic extract of T. peruviana was fractionated
by column chromatography. Briefly, 1.5 g of fruit extract
was adsorbed onto Celite 545 and subjected to reverse
flash chromatography on a 50 g RediSep Rf Gold HP C18
column, eluting with 10:90 MeOH-H2O for 4 CV. Then a
linear gradient from 10:90 MeOH-H2O to 100% MeOH
for 25 CV, holding 100% MeOH for 8 CV, at a flow rate of
40 mL/min to give 120 fractions each containing 12 mL.
The resulting fractions were then pooled according to
their ELSD and UV profiles, which resulted in six
combined fractions in total. All fractions were exam-
ined by UPLC-PDA-HRMS-MS/MS and tested for
cytotoxic activity against human prostate carcinoma
cell line (HTB-81) by the MTT colorimetric assay.
Cell lines and cell culture
The cancer cell lines used in this study were human
colorectal adenocarcinoma (HTB-38), lung carcinoma
(HTB-177), prostate adenocarcinoma (HTB-81), and breast
adenocarcinoma (HTB-22), whereas the normal cell lines
used were human skin fibroblast (CCL-116) and Vero cell
line (CCL-81). Cell lines were obtained from the American
Type Culture Collection (ATCC). Cell lines were cultured
in DMEM or RPMI (only for HTB-81) supplemented with
10% (v/v) fetal bovine serum (Byproductos). All cells were
cultured at 37 °C under a humidified atmosphere contain-
ing 5% CO2.
Cytotoxicity assay
For the cytotoxicity assay, 5 × 104-6 × 104 cells for colo-
rectal, lung, breast, prostate cancer cells, and normal cells
were seeded in 96-well tissue culture plates. When the
cells had reached 75% confluence, they were incubated
using the methanol extracts at various concentrations.
After 24 h of incubation, the cytotoxicity was assessed
using the MTT assay as described previously [12]. To
obtain the half maximal inhibitory concentration (IC50),
the percentages of cell viability and growth inhibition
were calculated according to the following equations
[13]. Cell viability (%) = [(OD of treated cells-OD of
blank)/ (OD of control-OD of blank)] × 100. Growth
inhibition (%) = 100 – Cell viability (%). All determina-
tions were performed five times independently with
three technical replicates.
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Clonogenic assay of cell in vitro
The clonogenic assay was carried out as previously de-
scribed [14]. 100–130 cells/well and incubated for 24 h
at 37 °C with 5% CO2 to lead attach. The cells were
treated with the corresponding IC50 for 24 h and were
cultured for 7–14 additional days. Then, the cultures
were stained with 0.5% crystal violet for 30 min. Col-
onies containing more than 50 cells (after 10–14 days of
incubation) were counted using ImageJ software [15].
Three independent experiments were performed with
three technical replicates each one.
Wound and healing assay
Wound and healing assay was carried out as previously
described [16]. 5 × 104–6 × 105 cells were seeded and
grown overnight to reach 100% confluency. The monolayer
was treated with the corresponding IC50 for 24 h. The cells
were migrated into the scratched area and photographed
(camera infinity 1–2, Lumenera Corp., CA) every 24 h.
The migrated cells were expressed as a mean value per
field. Three independent experiments were performed with
three technical replicates each one.
Cell morphology and membrane permeability assays
Cells were seeded in a 96-well plate for 24 h. After attach-
ment, the cells were treated with T. peruviana fruit extract
using the IC50 concentration for 4, 8, 16 and 24 h. For cell
morphology, the cells were observed using an inverted
microscope (Olympus IX71). Trypan blue assay was used
for the permeability assay (0.4% trypan blue/per well) [17].
As a negative control, cells were cultivated in the same
plate without the plant extract. Each sample was observed
under the microscope and photographs were taken imme-
diately after staining. Three independent experiments
were performed with three technical replicates.
DNA fragmentation analysis
DNA fragmentation was carried out as described previ-
ously [18]. Cells were grown in the presence or absence of
T. peruviana fruit extract using the IC50 concentration for
24 h. Doxorubicin treated cells were used as positive
control. Briefly, 5 × 105 cells were lysed in DNA lysis
buffer [1 M Tris-HCl (pH 8.0), 0.5 M EDTA, 100% Triton
X-100, 2% SDS, 0.2 M NaCl], and then, DNA was ex-
tracted. The nucleic acid concentration and purity were
measured using a NanoDrop® ND-2000 spectrophotometer
(Thermo Scientific). Equal amounts of DNA (10 μg/well)
were electrophoresed in 1% agarose gel. DNA fragments
were visualized using an UV transilluminator (MutilDoc-it
Digital Imaging System UVP). Three independent experi-
ments were performed.
Dual acridine orange/ethidium bromide (AO/EB)
fluorescent staining
For the AO/EB method, 5 × 105 cells were seeded in a
6-well plate. Cells were treated with T. peruviana fruit
extract at the corresponding IC50 concentration for 4 h.
Then cells were subjected to AO/EB staining as de-
scribed previously [19]. Briefly, cells were tripsinized and
re-suspended in cold PBS and AO/EB dye mix (100 μg/
mL AO and 100 μg/mL EB; Sigma) was added. Stained
cell suspensions (10 μL) were viewed and counted using
a Nikon eclipse TS100 inverted microscope at 40× mag-
nification with excitation filter 480/30 nm and barrier
filter 535/40 nm. Six fields per sample were examined.
The AO/EB staining method was repeated 3 times.
Liquid chromatography - Mass spectrometry analysis
HRESIMS data were collected and in positive and negative
ionization modes using a Thermo QExactive Plus mass
spectrometer (ThermoFisher) equipped an electrospray
ionization (ESI) source and via an Acquity UPLC system
(Waters Corp). The higher-energy collisional dissociation
(HCD) cell used a normalized collision energy of 30 eV for
all the compounds to obtain MS/MS data. The UPLC sep-
aration was performed using an Acquity BEH C18 column
equilibrated at 40 °C and a flow rate set at 0.3 mL/min. The
mobile phase consisted of 15% CH3CN–H2O (0.1% formic
acid) for 0.5 min, and then a linear gradient from 15%
CH3CN to 100% CH3CN over 6 min, and 1 min holding
100% CH3CN before returning to the starting conditions.
Samples were dissolved in MS grade methanol and filtered
through a 0.2 μm Acrodisc (Waters) filter. Tentative metab-
olite identification was performed by comparison of HRMS
data, UV maxima and fragmentation patterns (MS/MS
data) with those contained in the Dictionary of Natural
Products [20] reference compounds refined for Thevetia
plant metabolites.
Data Analysis
Statistical analysis was performed using GraphPad Prism
7 software. The p-value was analyzed in comparison to
the untreated samples using Student’s t-Test or using one-
way analysis of variance (ANOVA) followed by a Tukey
test for comparison between different treatment groups.
Differences were considered statistically significant at
p < 0.05. Results were expressed as mean ± SEM of data
obtained from tripled or quintuplet, independent experi-
ments. Multivariate analysis was performed using the R
3.2.5 environment. Three biological replicates for each cell
line were evaluated, and the variables used were the IC50,
the clonogenic assay (CL), the membrane permeability
(MP) and the wound-healing assay (WH). A standardized
principal component analysis (PCA) was performed with
“ade4” package [21], followed by an independent compo-
nent analysis (ICA) applied to the PCA patterns [22].
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Results
Cytotoxic activity of T. peruviana fruit methanol extract
on human prostate, breast, colorectal, and lung cancer
cell lines
In order to assess the cytotoxic effect of the T. peruviana
methanol extract on breast (HTB-22), colorectal (HTB-38),
prostate (HTB-81), and lung (HTB-177) cancer cell lines, a
MTT assay was performed. IC50 values indicate the con-
centration of the extract that inhibits the growth of 50% of
the cell population. The criteria of cytotoxicity established
by the U.S. National Cancer Institute (NCI) considers a
crude extract as active, moderately active, or inactive, when
the IC50 values are lower than 20 μg/mL, from 20 to
100 μg/mL, or higher than 100 μg/mL, respectively [23]. T.
peruviana methanol fruit extract induced strong cytotox-
icity in all four cancer cell lines (<20 μg/mL), but prostate
cancer cells showed the lowest IC50 after treatment with T.
peruviana extract (IC50, 1.91 ± 0.76 μg/mL; Table 1). In
contrast, the methanol extract of T. peruviana exhibited
moderate activity against Vero cells and it was inactive
against fibroblast cell line (Table 1). Accordingly, the T.
peruviana fruit extract is cytotoxic to human cancer cell
lines, but moderately active on Vero cells and inactive on
healthy human fibroblast cells.
T. peruviana fruit methanol extract inhibits the
proliferative ability of four human cancer cell lines
The effect of the T. peruviana extract on colony forming
ability in four cancer cell lines was investigated. Clono-
genic assay was carried out to assess the differences in
reproductive viability between treated and untreated cells
with T. peruviana extract. One hundred cancer cells were
seeded in the presence or absence of T. peruviana extract,
and after 10–15 days of incubation, the colonies formed
were counted. The number of colonies observed was sig-
nificantly inhibited by the T. peruviana extract (Fig. 1a).
Colony forming ability was reduced by 80% in the breast
and prostate cancer cells, while colorectal and lung cancer
cells were reduced by 70% (Fig. 1b). In contrast, no defect
in proliferation ability was observed for normal cell lines
(Fig. 1a, b). Positive control (doxorubicin) inhibited the
colony forming ability of both cancer and normal cell lines
(Additional file 1: Figure S1). These results suggest that
the T. peruviana fruit extract has strong anti-proliferative
activity against different types of cancer cells without
displaying alterations on normal cell lines.
T. peruviana fruit extract affects the cell motility of
human cancer cell lines
The effect of the T. peruviana fruit extract on cell motil-
ity was researched using a wound-healing assay. Cancer
cells were evaluated in the presence or absence of the
plant extract, monitoring until the induced wound was
completely closed. Untreated cells exhibited complete
wound closure at 24, 48, 96, and 144 h for the human
prostate, breast, lung, and colorectal cancer cell lines, re-
spectively. In contrast, all cancer cell lines evaluated
showed a dramatic inhibition of wound closure when
treated with the T. peruviana extract. The wound clos-
ure of Vero and fibroblast cells was achieved at 48 h,
whether exposed to the fruit extract or not (Additional
file 2: Figure S2). As a positive control, doxorubicin was
used in wound-healing assay and showed an increase in
the wound due to strong detachment of both the human
cancer and normal cell lines (Additional file 3: Figure S3).
These results indicated that the T. peruviana fruit extract
inhibited and delayed the migration of four different
human cancer cells in vitro.
Morphological changes in four human cancer cell lines
exposed to T. peruviana extract
All the human cell lines displayed significant morphological
changes when treated with T. peruviana fruit extract for
24 h (Fig. 2). Thus, we checked whether changes in cell
morphology occurred during the incubation of the cells
with media containing plant extract. Morphological
changes of human cancer cells treated with plant extract
were monitored up to 24 h. At 8 h of incubation, some cells
were rounded up in the prostate, lung, and breast cancer
cells. After 16 h of treatment, the cells had shrunk and
showed disrupted intercellular contacts. In some cases, the
cells were bi-nucleated and the majority of the cells were
detached from the wells, denoting cell death. These changes
were more drastic for the prostate, breast, and lung cancer
cell lines than for colorectal cells and the most prominent
effect in the latter was membrane blebbing (small protru-
sions of the membrane). Because cells did not show vacuol-
ation in the cytoplasm, we considered that autophagy is not
involved in the mechanism of cell death [24]. To highlight,
Table 1 IC50 values of T. peruviana fruit extract on prostate, lung, colorectal and breast cancer cell lines
IC50 (μg/mL) ± SEM
Cancer cell lines Normal cell lines
Prostate Breast Colorectal Lung Vero Fibroblast
1.91 ± 0.76a 5.78 ± 2.12a 6.30 ± 4.45a 12.04 ± 3.43a 57.02 ± 14.8b 1578 ± 301c
Human cancer cell lines were treated with different concentrations of T. peruviana fruit extract in 96-well microcultured plates for 24 h. IC50 values are expressed
as mean ± standard error of mean (S.E.M) of quintuplicate determinations. Different letters represent statistically significant differences determined by one way
ANOVA (ρ < 0.05), followed by Tukey’s multiple comparison test
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normal cell lines showed no evident morphology alteration
during the 24 h of treatment with T. peruviana fruit extract.
When control treatment with doxorubicin was applied, cell
morphology was altered in both human cancer and normal
cells (Additional file 4: Figure S4). These results indicated
that after 8 h of exposure to the T. peruviana extract, the
cancer cells presented significant morphological alterations
without any observed change in the healthy cell lines.
T. peruviana extract affects the viability of human cancer
cells in a time-dependent manner
To determine whether the viability of the human cancer
cells is affected during treatment with T. peruviana ex-
tract, the trypan blue exclusion test was used. Loss of
the integrity of plasma membrane can be verified using
polar dyes, such as trypan blue, which is excluded by an
intact membrane. We observed that the number of dead
cells increased in a time-dependent manner in the pres-
ence of the extract plant. The effect of the T. peruviana
extract on cell viability of the breast and prostate cancer
cells was 50–60% viability after 8 h of treatment,
whereas the lung and colorectal cancer cells had 80%
viability after 8 h. After 24 h, the lung, prostate, and
breast cancer cells showed viability decreased to below
25% (Fig. 3). Interestingly, the colorectal cancer cells
were less sensitive to plant extract showing 70% of via-
bility after 24 h treatment. Vero and fibroblast cells
showed a small decrement or none at all in viability dur-
ing the treatment with the T. peruviana fruit extract.
This result confirms that T. peruviana extract has a
cytotoxic effect (at the level of membrane integrity) on
different types of cancer cells whereas the normal fibro-
blast cells were not affected.
Motility and membrane permeability features are mainly
affected by T. peruviana fruit extract
Multivariate analysis was performed on the six cell lines
(four tumoral and two normal), using as variables to be
evaluated: the IC50 value, the clonogenic assay, the
wound healing assay, and membrane permeability. PCA
was applied to the whole dataset and the first 3 principal
components (PC’s) accounted for 97.3% of the observed
variability. Assuming that directions with the greatest
variance are the most biologically relevant, these leading
PC’s were selected as those with the major structure or
variance, as a de-noising step enhancing ICA results.
ICA obtained 3 independent components (IC1, IC2 and
IC3) with negative kurtosis (−1.62, −1.42 and −0.12, re-
spectively). The employment of these components, plot-
ting IC1 and IC2, allowed the effective separation of
samples into their original groups (Fig. 4). With this,
ICA was able to distinguish between the sensitivity of
normal (right side) and cancer cells (left side) exposed to
T. peruviana extract (with colorectal cancer cell between
both populations). The IC1 clearly separates tumor cells
from normal cells, mainly due to the effect of the extract
on cell motility (wound healing assay) and the mem-
brane permeability, while the IC2 separates samples
mainly on the basis of the IC50 observed for each cell
line. The anti-proliferative (clonogenic assay) response
of the cell lines to the extract is mainly represented by
the IC3, which can be observed in the Additional file 5:
Figure S5. Overall, this analysis identified that the main
features affected by the T. peruviana extract were cell
motility and membrane permeability and, less signifi-
cantly, the IC50 and anti-proliferative activity.
T. peruviana fruit extract induces DNA fragmentation in
four types of human cancer cells
The detection of the DNA fragmentation is a common
hallmark of cells undergoing late-stage apoptosis [25]. In
order to determine if T. peruviana fruit extract could in-
duce DNA fragmentation and thus whether apoptosis
occurred, human cancer cells exposed to T. peruviana
treatment were assessed for DNA laddering and visualized
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Fig. 1 Clonogenic assay of four human cancer cell lines treated with
methanol T. peruviana extract. a Image showing colonies produced
by human cancer lines following plating of 100 cells and 10–14 days
incubation. Cells were treated with IC50 value corresponding for each cell
line; b cells were quantified and error bar indicates mean ± SEM of three
independent experiments. The level of significance was determined
using Student’s t-Test with nsrepresenting ρ > 0.05, **** indicates
ρ < 0.0001, ** indicates ρ < 0.01 and * indicates ρ < 0.05
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by agarose gel electrophoresis (Fig 5). It was found that
the four human cancer cell lines incubated with T. peruvi-
ana extract showed apoptotic DNA fragmentation profiles
similar to the positive control, doxorubicin, which is
known to induces apoptosis [26]. No nucleic acid frag-
mentation was observed in untreated cells. Normal cell
lines showed a lower degree of DNA fragmentation com-
pared with cancer cell lines.
Apoptosis induction by T. peruviana fruit extract on
human lung and prostate cancer cells
It was observed that T. peruviana extract triggered mor-
phological changes and DNA fragmentation in a time-
dependent manner that could be related to apoptosis.
To determine and quantify cell death, acridine orange/
ethidium bromide (AO/EB) fluorescent staining was
used to identify apoptosis-associated changes in the cell
membrane. AO is a membrane-permeable dye that binds
to the nucleic acids of viable cells. EB is an impermeable
dye, but readily penetrates the membrane of nonviable
cells and binds to DNA. When AO/EB are used simul-
taneously, viable cells fluoresce green and nonviable cells
fluoresce red under fluorescence microscopy. Lung and
prostate cells were labeled by AO/EB after 4 h of treat-
ment with the T. peruviana extract, and dual staining
was examined under a fluorescent microscope. Early and
late-stage apoptotic cells, marked by crescent-shaped or
granular yellow-green AO nuclear staining (as indicated
by condensed or fragmented chromatin) were detected
in the treated group (with T. peruviana extract) and the
positive control (doxorubicin treated) (Fig. 6a). Also,
dead cells from direct necrosis were detected, having an
orange nucleus. No significant apoptosis was detected in
the negative control group (untreated cells), which
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showed a normal green nucleus. Quantification of the
live, apoptotic, and necrotic cell populations in the con-
trol and treated human prostate and lung cancer cells
indicated that after 4 h of treatment, the prostate and
lung cancer cells increased the early apoptosis stage by
40.65% and 41.51%, respectively (Fig. 6b). Thus, in ac-
cordance with our DNA fragmentation results, the T.
peruviana fruit extract triggers apoptosis.
Metabolic profiling of T. peruviana fractions by LC-MS
analysis
Methanol extract of T. peruviana fruit was subjected to
flash chromatography and six fractions were obtained.
Because prostate cancer cells showed the lowest IC50 to
T. peruviana crude extract compared to lung, breast,
and colorectal cancer cells, every single fraction was ana-
lyzed on the prostate cancer cell line by MTT assay,
fractions four and five being the most significantly cyto-
toxic (Table 2). Those fractions were analyzed using
UPLC-PDA coupled with a HRESIMS-MS/MS spectrom-
eter. Each peak contained in the fractions was dereplicated
for their UV profile, HRMS data in both positive and
negative modes, and for its MS/MS fragmentation pattern
against a refined subset of plant metabolites of Thevetia
species contained in the Dictionary of Natural Products
(286,310 compounds contained in the database). The re-
sults showed that these fractions contained the polyketide
thevetiaflavone and the cardiac glycosides: peruvosidic
acid, peruvoside, thevefoline, solanoside, neriifoside and
neriifolin.
Discussion
T. peruviana belongs to the Apocynaceae family, a plant
which is native to central and southern Mexico, as well
as Central America. It is a medicinal plant used to treat
different diseases, including cancer [27]. The leaves of
yellow oleander had previously been studied and shown
to possess antimicrobial, antifungal, antidiarrheal, insecti-
cide, molluscacide, and rodenticide activity [8, 28–30].
However, scientific evidence to demonstrate mode of ac-
tion, targets and agents responsible for the bioactivity in
the fruit is still needed. The purpose of the present study
was to find out the cytotoxic and anti-proliferative activity
of methanol extracted fruit of T. peruviana on different
types of human cancer cell lines.
Our experiments in vitro showed that T. peruviana
fruit extract exhibited strong cytotoxicity against four
cancer cell lines. Among the cell lines examined, lung
cells showed higher IC50 value (12.04 μg/mL) than
IC50
WH
CL
Fig. 4 Classification of normal and cancer cell lines exposed to T.
peruviana fruit methanolic extract according to independent component
analysis (ICA). The distribution of the cell lines (panel A, projections with
95% confidence ellipses) and variables (panel B, projection of variable
loadings, with maximum loading indicated by a circle) is shown in the
space spanned by the two leading independent components. The clear
unsupervised discrimination among the six cell lines reflects the greater
effect of T. peruviana extract on tumor cell lines (lung cells, L, ●, prostate
cells, P, ■, breast cells, B, ♦, colorectal cells, C, ▲), while normal cells are
less affected (fibroblast cells, Fb, □, Vero cells, V, ○). The independent
component 1 is clearly separating cancer cells from normal cells, mainly
due to the effect of the extract on the motility (WH) and membrane
permeability (MP), while the independent component 2 is separating
samples mainly by the IC50 value observed for each cell line
m    C     E    D    C     E    D       m    C     E    D    C    E    D         m    C    E    D     C    E    D
Lung Prostate Breast Colorectal FB VERO
3000 pb
1500 pb
400 pb
1000 pb
Fig. 5 DNA fragmentation of human cancer cell lines treated with T. peruviana methanol extract. Lung, prostate, breast and colorectal cancer cell
lines were treated with the corresponding IC50 value for each cell line during a 24 h period; m, molecular-weight marker; C, untreated control; E,
cancer cell line treated with T. peruviana methanol extract at its corresponding IC50 value and, D, cancer cell line treated with doxorubicin (10 μg/
mL). Representative result from three independent experiments is shown
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prostate (1.91 μg/mL), breast (5.78 μg/mL), and colorectal
(6.30 μg/mL) cells. Such variation among the cell lines
might be attributed in part to the fact that cancer cells
possess differences in their genetic make up, morphology
and doubling time, resulting in differential susceptibility
to the same cytotoxic agent [31]. Our results, together
with previously reported toxic activity, suggest that T.
peruviana fruit methanol extract has an antiproliferative
potential.
Cancer is a complex disease characterized by prolifera-
tion of highly resistant cells to death. An increased rate
of cellular proliferation is frequent, due to the fact that
most cancer cells divide more often than normal cells.
The goal of targeting cell proliferation is to arrest the
cell cycle or induce cancer cell death using cytotoxic
compounds. We show here, that T. peruviana fruit ex-
tract significantly reduced the cell viability and the abil-
ity of cells to form colonies in four different human
cancer cell lines. The clonogenic assay has been used to
detect cells that have retained their capacity to produce
a large number of progeny after radiation and chemo-
therapy treatments [32]. It also correlates tumorigen-
icity analysis in vivo and predicts the clinical response
toward several agents in breast cancer patients [33].
Hence, our results in clonogenic assay suggest that T.
peruviana fruit extract has potential anticancer activity,
limiting proliferation of cancer cells after treatment.
Notably, normal cells (vero and fibroblast) treated with
Untreated +Ext +DoxA
B
Pr
os
ta
te
L
un
g
Un
tre
at
ed
+E
xt
+D
ox
0
20
40
60
80
100
Prostate
%
 o
f 
ce
lls
a
a a a
b
b
b
c
c
Un
tre
at
ed
+E
xt
+D
ox
0
20
40
60
80
100
Lung
%
 o
f 
ce
lls
a
a
b
b
bb
Live
Early apoptosis
Late apoptosis
Necrotic
L
L
L A
L A
E A
E A
N
N
L
Fig. 6 AO/EB double stain of human cancer cell lines after a treatment with T. peruviana methanol extract. a. Prostate and lung cells were treated
with IC50 of T. peruviana methanol extract. Images represent the control (untreated cells), treated cells and, cell treated with doxorubicin (10 μg/mL) as
positive control. Cells were stained with acridine orange and ethidium bromide (AO/EB) after 4 h of treatment. White arrows indicate live (L), early
apoptotic (EA), late apoptotic (LA) or necrotic (N) cells. b. Error bar indicates mean ± SEM of three independent experiments. +Ext and +Dox, both
indicate cells treated with extract or doxorubicin. Different letters represent statistically significant differences determined by one way ANOVA
(ρ < 0.05) between bars with same color by cell line. Non-letter bars have no statistical difference
Table 2 Cell viability of the fractions of T. peruviana fruit extract
on prostate cancer cell line (HTB-81)
Fraction % Viability
1 116 ± 3.7a
2 121 ± 5a
3 103 ± 4a
4 3.71 ± 3.4b
5 1.24 ± 1.9b
6 62 ± 3c
The fractions were obtained by flash chromatography. Viability was determined by
MTT assay, values being expressed as mean ± SEM of triplicate determinations.
Different letters represent statistically significant differences determined by one
way ANOVA (ρ < 0.05), followed by Tukey’s multiple comparison test
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T. peruviana extract did not show any observable effect
in clonogenic assay.
Migration is a critical step in initial progression of can-
cer that facilitates metastasis. Wound and healing assay
is a classic and common method used for discovery and
validation of molecules that affect cell migration [16, 34]
and metastasis [35]. The methanolic T. peruviana fruit
extract inhibited and delayed the cell migration of can-
cer cells, but not among normal cells. These results open
the door to further studies that could confirm if the
cytotoxic activity of T. peruviana fruit extract alters the
regulation of the actin cytoskeleton, induces morphological
changes and leads to detachment of cells, culminating in
cell death. Moreover, motility and membrane permeability
features were mainly affected by T. peruviana fruit extract,
according with the multivariate analysis performed on the
six cell lines and the four variables evaluated, suggesting a
potential antimetastatic activity in the T. peruviana fruit
extract.
One crucial and desirable mechanism by which che-
motherapeutics destroy tumor cells is by inducing apop-
tosis. Cells undergoing apoptosis show morphological
and biochemical modifications including chromatin segre-
gation, nuclear condensation, DNA fragmentation, parti-
tion of the membrane, and vesicles formation [36, 37].
The late-stage of apoptosis can be visualized by standard
agarose gel electrophoresis as a ladder pattern due to
DNA cleavage [38], while both (the early and late stages of
apoptosis) can be determined by AO/EB fluorescent stain-
ing. Cerbera manghas, a plant belonging to the Apocyna-
ceae family, contains a cardiac glycoside (neriifolin), which
induced DNA fragmentation on hepatocellular carcinoma
48 h after treatment [39]. Here, crude extract from T. per-
uviana fruit showed death induction on cancer cell lines
through early apoptosis mechanisms (AO/EB fluorescent
staining) 4 h after treatment and late-stage apoptosis
(DNA laddering assay) after 24 h of treatment. This result
indicates that T. peruviana could have a higher level of
apoptotic activity than other members of the Apocynaceae
family. In addition, it will be important to determine
whether the apoptotic activity is located in the compounds
present in the flesh or seeds.
Mass spectrometry analysis of active fractions from T.
peruviana fruit methanol extract indicated that one fla-
vonoid and cardiac glycosides are secondary metabolites
present in the fruit plant. Flavonoids, such as curcumin,
quercentin and genistein, are known to have cell line-
specific anti-proliferative and apoptosis inducing activity
[40–42]. It has been postulated that flavonoids possess
anticancer properties manifested through several mecha-
nisms, including decrease of reactive oxygen species, in-
hibition of DNA topoisomerase and downward regulation
pathway of nuclear transcription factors [43–46]. Further
experiments are required to determine the cytotoxic effect
of thevetiaflavone and individual cardiac glycosides
present in the methanolic fruit extract of T. peruviana
on human cancer cell lines. Recent investigations of
seeds from T. peruviana resulted in the isolation of car-
diac glycosides that had inhibitory effects against human
gastric and pancreatic cancer cell lines [11]. Cardiac glyco-
sides are the most researched secondary metabolites in T.
peruviana due to the fact they can heal heart pathologies
[47], but are also being studied for their cytotoxic and/or
apoptotic activities against myeloid leukemia (peruvoside)
[48] and hepatocellular carcinoma (neriifolin) [39]. Theve-
tin and peruvoside are cardiac glycosides which are clinic-
ally important constituents due to be used in treatment of
arrhythmias [49]. One hundred nine cardenolides have
been isolated and identified from members of the Apocy-
naceae family, and about a quarter of them are reported to
have anticancer activity. Cardenolides are well known as
the substrates of Na+/K + −ATPase, which is an enzyme
that regulate various cell survival and death signal path-
ways [6] and its relative distribution and expression are
distinct in cancer cells compared with normal ones, indi-
cating that they could serve as a novel target with great
potential. This could be the reason that multivariate ana-
lysis showed an adequate separation between normal and
cancer cells, revealing significant differences in their sensi-
tivity to the toxic compounds in the T. peruviana fruit
methanolic extract, mainly due to the effect of the extract
on the motility and membrane permeability on human
prostate, breast, colorectal and lung cancer cell lines. The
cytotoxic activity of crude extract from T. peruviana fruit
could be attributed to their phytochemical components
such as thevetin A, thevetin B, peruvoside, thevenerin,
and cerberin, which are toxins [50], and also to the cardiac
glycosides found in active fractions reported in this study
(thevefoline, solanoside, neriifoside, peruvoside and nerii-
folin). Finally, the isolation of the active principles of the
methanolic extract of T. peruviana fruit is currently being
undertaken to investigate their cytotoxic, molecular and
genetic action mechanisms, which could provide mean-
ingful perspectives for biomedical and biotechnological
research.
Conclusions
The current study presents evidence that the methanol
extract of T. peruviana fruit inhibits cell proliferation,
has a time-dependent cytotoxic activity and induces
apoptosis of human cancer cell lines, but has minimal or
less pronounced effects on normal cells. The fruit extract
displayed anticancer properties mainly through mecha-
nisms that included membrane permeability, motility and
DNA fragmentation. Maximum cytotoxic activity was ob-
served in a fraction that contained one flavonoid and car-
diac glycosides. Chemical analyses of the active fractions
are currently in progress to perform a better evaluation of
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their biological significance. Additionally, further “in vivo”
research is essential to show the full potential for the use
of T. peruviana fruit extract in cancer therapy. In conclu-
sion, these findings shows the importance of T. peruviana
fruit as a source of bioactive compounds with anticancer
potential.
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Additional file 2: Figure S2. Wound and healing closure activity of
four human cancer cell lines treated with methanol T. peruviana extract.
Representative photographs of wounded cancer cells monolayer after
24 h of treatment with methanol T. peruviana fruit extract at IC50 value
corresponding to each cell line. Vero and fibroblast cells were used as
normal cell lines. A typical result from three independent experiments is
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photographs of wounded cancer cells monolayer after 24 h of treatment
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Additional file 4: Figure S4. Morphological changes on four human
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Additional file 5: Figure S5. Classification of normal and cancer cell
lines exposed to T. peruviana fruit methanolic extract according to
independent component analysis (ICA). The distribution of the cell lines
(panel A, projections with 95% confidence ellipses) and variables (panel B,
projection of variable loadings with maximum loading indicated by a
circle) is shown in the space spanned by the independent components 1
and 3. The clear unsupervised discrimination among the six cell lines
reflects the greater effect of T. peruviana extract on tumor cell lines (lung
cells, L, ?, prostate cells, P, ¦, breast cells, B, ?, colorectal cells, C, ?), while
normal cells are affected less (fibroblast cells, Fb, ?, Vero cells, V, ?). The
independent component 1 is clearly separating cancer cells from normal
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